The Emergence of PROTAC Technology In the realm of modern drug discovery, the term "PROTAC" has become increasingly prevalent. PROTAC stands for "Proteolysis Targeting Chimeras," a revolutionary technology that offers an innovative approach to degrading specific proteins within cells. Unlike traditional small-molecule drugs, which typically inhibit the function of a target protein, PROTACs work by recruiting an E3 ubiquitin ligase to the target protein, marking it for degradation by the cell's proteasome. This novel mechanism opens up new avenues for therapeutic interventions, particularly for diseases where conventional drugs have failed. Understanding PROTAC Libraries A PROTAC library is a collection of diverse PROTAC molecules, each designed to target different proteins for degradation. The creation of these libraries is critical for high-throughput screening and identifying potent PROTAC candidates for specific therapeutic targets. Researchers compil

Custom synthesis has emerged as a critical component in the pharmaceutical, biotechnology, and specialty chemical industries. It involves the creation of unique chemical compounds tailored to the specific needs of clients, enabling innovation, efficiency, and precision in various applications. This article explores several key areas of custom synthesis, including custom lipid synthesis, active pharmaceutical ingredient (API) synthesis, flavors and fragrance synthesis, and peptide synthesis. Custom Lipid Synthesis Lipid synthesis plays a vital role in biochemistry and pharmaceuticals, especially given the increasing significance of lipid-based formulations in drug delivery systems. Custom lipid synthesis refers to the tailored production of various lipid molecules, including phospholipids, fatty acids, and sphingolipids, which are crucial for creating liposomes, micelles, and emulsions that encapsulate therapeutic agents. Recent advances in lipid technologies have driven the dema

The clinical results and potential commercial value of drug conjugates, especially antibody drug conjugates (ADCs), have fueled the enthusiasm for M&A deals between companies and attracted widespread industry attention. Technological advances have also led to a collision of old and new concepts of drug conjugates, challenging even the current stage of drug conjugates concepts and technologies.

Currently, one of the most important challenges when designing a good ADC drug is to maximize its effectiveness while minimizing the non-target toxicity. In order to achieve a balance between safety and effectiveness, it is necessary to adjust and optimize each of the three structural elements of ADCs: antibody backbone, payload (cytotoxin), and a combination (linker) between them. We provide ADC services to meet clinical and commercial development needs. Our strong expertise in process development, characterization, optimization, and scale-up can support successful GMP manufacturing and productive long-term cooperative relationships with pharmaceutical companies, institutions, and universities.

The analysis of impurities in drugs is a very important part. This paper focuses on the important role of the source analysis of impurities and focuses on the development of analytical techniques in the process of impurity research, especially the development of mass spectrometry technology in structure identification. Source analysis of impurities Impurities in a drug can arise from manufacturing as well as distribution. According to ICH guidelines, drug impurities can be divided into organic impurities, inorganic impurities, residual solvents, and other impurities. The concept of "Quality by Design (QbD)" is introduced in the study of drug impurities, which can initially delineate the impurity spectrum of the product according to the synthesis mechanism of the specific process, the starting material, and the basic structure of each intermediate before drug production. Source analysis of impurities is the basis for formulating drug impurity control strategies, especially

The analysis of impurities in drugs is a very important part. This paper focuses on the important role of the source analysis of impurities and focuses on the development of analytical techniques in the process of impurity research, especially the development of mass spectrometry technology in structure identification. Source analysis of impurities Impurities in a drug can arise from manufacturing as well as distribution. According to ICH guidelines, drug impurities can be divided into organic impurities, inorganic impurities, residual solvents, and other impurities. The concept of "Quality by Design (QbD)" is introduced in the study of drug impurities, which can initially delineate the impurity spectrum of the product according to the synthesis mechanism of the specific process, the starting material, and the basic structure of each intermediate before drug production. Source analysis of impurities is the basis for formulating drug impurity control strategies, espe